News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
362,335 Results
Type
Article (14407)
Company Profile (115)
Press Release (347813)
Section
Business (112639)
Career Advice (455)
Deals (18611)
Drug Delivery (28)
Drug Development (31155)
Employer Resources (49)
FDA (8789)
Job Trends (7669)
News (172746)
Policy (12361)
Tag
Academia (1318)
Alliances (34740)
Alzheimer's disease (483)
Approvals (8794)
Artificial intelligence (198)
Bankruptcy (130)
Best Places to Work (6522)
Biotechnology (86)
Breast cancer (96)
Cancer (818)
Career advice (405)
CAR-T (82)
Cell therapy (227)
Clinical research (24255)
Collaboration (490)
Compensation (87)
COVID-19 (1135)
C-suite (97)
Data (763)
Diabetes (77)
Diagnostics (4862)
Earnings (38206)
Events (50825)
Executive appointments (316)
FDA (9251)
Funding (395)
Gene editing (69)
Gene therapy (144)
GLP-1 (210)
Government (1229)
Healthcare (9875)
Infectious disease (1196)
IPO (7987)
Job creations (1434)
Job search strategy (361)
Layoffs (114)
Legal (2518)
Lung cancer (104)
Manufacturing (148)
Medical device (11402)
Medtech (11407)
Mergers & acquisitions (10879)
Metabolic disorders (172)
Neuroscience (631)
NextGen: Class of 2025 (3534)
Non-profit (1518)
Northern California (901)
Obesity (76)
Opinion (73)
Patents (99)
People (32530)
Phase I (8959)
Phase II (10956)
Phase III (7091)
Pipeline (323)
Postmarket research (501)
Preclinical (4024)
Press Release (66)
Radiopharmaceuticals (152)
Rare diseases (120)
Real estate (3357)
Regulatory (9241)
Research institute (1266)
Resumes & cover letters (68)
Series A (73)
Southern California (965)
Startups (2503)
United States (9459)
Vaccines (281)
Date
Today (3)
Last 7 days (306)
Last 30 days (1319)
Last 365 days (18195)
2025 (2384)
2024 (18710)
2023 (22099)
2022 (30813)
2021 (32514)
2020 (30545)
2019 (25809)
2018 (19470)
2017 (18877)
2016 (17761)
2015 (20560)
2014 (15177)
2013 (12743)
2012 (13783)
2011 (14071)
2010 (12831)
Location
Africa (317)
Arizona (110)
Asia (23874)
Australia (4155)
California (2336)
Canada (912)
China (188)
Colorado (139)
Connecticut (114)
Europe (48768)
Florida (371)
Georgia (112)
Illinois (243)
Indiana (132)
Japan (83)
Kansas (78)
Maryland (388)
Massachusetts (1630)
Michigan (171)
Minnesota (214)
New Jersey (729)
New York (680)
North Carolina (465)
Northern California (901)
Ohio (91)
Pennsylvania (484)
South America (504)
Southern California (965)
Texas (369)
Utah (83)
Washington State (284)
362,335 Results for "palatin technologies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Palatin Provides Update on Anticipated 2025 Corporate Milestones
January 28, 2025
·
6 min read
Press Releases
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
February 7, 2025
·
5 min read
Press Releases
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
February 14, 2025
·
12 min read
Press Releases
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
February 11, 2025
·
1 min read
Press Releases
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
February 6, 2025
·
5 min read
Drug Development
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced the initiation of a Phase 2 clinical study of bremelanotide for the treatment of obesity.
June 12, 2024
·
6 min read
Drug Development
Palatin’s Dry Eye Drug Candidate Flops in Phase III Trial
Palatin Technologies’ melanocortin agonist PL9643 came up short in a late-stage study evaluating its safety and efficacy.
March 1, 2024
·
2 min read
·
Tyler Patchen
Deals
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
Palatin Technologies, Inc. today announced that it has entered into a warrant inducement agreement with an institutional investor to exercise certain outstanding warrants that the Company issued in November 2022 and October 2023 totaling 3,233,277 shares of the Company’s common stock for gross proceeds of approximately $6.1 million.
June 21, 2024
·
4 min read
Press Releases
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
December 17, 2024
·
4 min read
Deals
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
Cosette Pharmaceuticals Acquires Vyleesi ® (Bremelanotide Injection) from Palatin Technologies Inc.
January 3, 2024
·
3 min read
1 of 36,234
Next
